FIA
ZVRA icon

FNY Investment Advisers’s Zevra Therapeutics ZVRA Stock Holding History

FNY Investment Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-234
Closed -$1K – 865
2023
Q4 		$1K Buy
+234
New +$1.09K ﹤0.01% 454

Other funds holding ZVRA

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $246M AUM 27.83% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

FNY Investment Advisers's ZVRA Position: Q1 2024 in Review

FNY Investment Advisers sold out of Zevra Therapeutics (ZVRA) in Q1 2024, closing a stake of 234 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in ZVRA in Q4 2023 and held it in 1 quarter. The position peaked at $1K in Q4 2023. 89 funds tracked by Wall St. Rank hold ZVRA as of Q1 2024.

  • FNY Investment Advisers reported no remaining Zevra Therapeutics position as of Q1 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 234 Zevra Therapeutics shares in Q1 2024, an estimated $1K.
  • FNY Investment Advisers first reported a position in Zevra Therapeutics in Q4 2023 and held it in 1 quarter.
  • FNY Investment Advisers's Zevra Therapeutics position peaked at $1K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2024.

Based on FNY Investment Advisers's 13F filing for Q1 2024, filed 3 May 2024.